This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignees: Hasumi, LLC, University System of Maryland. Active years: 2010-2012.
Company Filing History:
2 out of 2 
2 out of 2,025 
Years Active: 2010-2012
Title: Kim Graulich Hankey: Innovator in Vaccine Adjuvants
Introduction
Kim Graulich Hankey is a notable inventor based in Edgewood, MD (US). She has made significant contributions to the field of immunotherapy through her innovative work on vaccine adjuvants. With a total of 2 patents, her inventions aim to enhance the immune response in patients receiving vaccines or cancer treatments.
Latest Patents
Hankey's latest patents include the "Human lymphocyte vaccine adjuvant" and the "Human lymphocyte medium adjuvant." Both inventions relate to adjuvants derived from human lymphocytes. These adjuvants can be used in combination with traditional vaccines or cancer immunotherapy to improve the patient's immune response. The adjuvants are derived from the supernatant collected from cultured activated lymphocytes, showcasing her innovative approach to enhancing immunotherapeutic efficacy.
Career Highlights
Throughout her career, Kim Graulich Hankey has worked with various organizations, including Hasumi, LLC and the University System of Maryland. Her experience in these institutions has allowed her to develop her groundbreaking inventions and contribute to advancements in the field of immunology.
Collaborations
Some of her notable coworkers include Kenichiro Hasumi and Dean LeMar Mann. Their collaboration has likely played a role in the development of her innovative adjuvants.
Conclusion
Kim Graulich Hankey's work in developing human lymphocyte-derived adjuvants represents a significant advancement in vaccine technology. Her contributions are poised to enhance the effectiveness of immunotherapies and traditional vaccines, ultimately benefiting patient care.